Soranib Tablets
Soranib Tablets

Soranib Tablets

Buyer Feedback
Posted by : Mr Bhavesh Shah
Offered by : PHAMAZON OVERSEAS PVT. LTD.
Last updated on : Aug 21,2015
Product added on : Sep 06,2014
Product Code : AC-SB
Send Inquiry Have a question?   Ask Supplier
Product Description

SORANIB IS EQUIVALENT AS NEXAVAR, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate is a white to yellowish or brownish solid with a molecular formula of C21H16ClF3N4O3 x C7H8O3S and a molecular weight of 637.0 g/mole. Sorafenib tosylate is practically insoluble in aqueous media, slightly soluble in ethanol and soluble in PEG 400. Each red, round NEXAVAR film-coated tablet contains sorafenib tosylate (274 mg) equivalent to 200 mg of sorafenib and the following inactive ingredients: croscarmellose sodium, microcrystalline cellulose, hypromellose, sodium lauryl sulphate, magnesium stearate, polyethylene glycol, titanium dioxide and ferric oxide red.

More
About the Supplier

Established in 2017, PHAMAZON OVERSEAS PVT. LTD. has been a leading name in offering top notch Health Care Products. Located in Mumbai, Maharashtra, we offer the best quality Soranib Tablets to our customers at best prices in the industry.

  • Nature of Business
    Exporter / Importer / Manufacturer / Wholesaler/Distributor / Supplier / Trading Company
  • Number of Employees
    18
  • Year of Establishment
    2017
  • Annual Turnover
    Rs 2 Crores
  • Working Days
    Monday - Saturday
Send your inquiry directly to this supplierReceiver's Company Name: PHAMAZON OVERSEAS PVT. LTD.

* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.

Send this inquiry to other Suppliers of similar products (?)
I agree to abide by all the Terms and Conditions of tradeindia.com
Contact Details
PHAMAZON OVERSEAS PVT. LTD.
1/a Empress Business Bay, Near Uti Mutual Fund, Road No 11, Midc, Andheri East,
Mumbai, Maharashtra, 400093, India
Contact Supplier
Call Me Free
Last updated on : 25 June 2018 Report Incorrect Contact